title: Novel therapeutics for coronary artery disease from genome-wide association study data.
abstract: BACKGROUND
  Coronary artery disease (CAD), one of the leading causes of death globally, is influenced by both environmental and genetic risk factors. Gene-centric genome-wide association studies (GWAS) involving cases and controls have been remarkably successful in identifying genetic loci contributing to CAD. Modern in silico platforms, such as candidate gene prediction tools, permit a systematic analysis of GWAS data to identify candidate genes for complex diseases like CAD. Subsequent integration of drug-target data from drug databases with the predicted candidate genes can potentially identify novel therapeutics suitable for repositioning towards treatment of CAD.
  
  
  METHODS
  Previously, we were able to predict 264 candidate genes and 104 potential therapeutic targets for CAD using Gentrepid (http://www.gentrepid.org), a candidate gene prediction platform with two bioinformatic modules to reanalyze Wellcome Trust Case-Control Consortium GWAS data. In an expanded study, using five bioinformatic modules on the same data, Gentrepid predicted 647 candidate genes and successfully replicated 55% of the candidate genes identified by the more powerful CARDIoGRAMplusC4D consortium meta-analysis. Hence, Gentrepid was capable of enhancing lower quality genotype-phenotype data, using an independent knowledgebase of existing biological data. Here, we used our methodology to integrate drug data from three drug databases: the Therapeutic Target Database, PharmGKB and Drug Bank, with the 647 candidate gene predictions from Gentrepid. We utilized known CAD targets, the scientific literature, existing drug data and the CARDIoGRAMplusC4D meta-analysis study as benchmarks to validate Gentrepid predictions for CAD.
  
  
  RESULTS
  Our analysis identified a total of 184 predicted candidate genes as novel therapeutic targets for CAD, and 981 novel therapeutics feasible for repositioning in clinical trials towards treatment of CAD. The benchmarks based on known CAD targets and the scientific literature showed that our results were significant (p < 0.05).
  
  
  CONCLUSIONS
  We have demonstrated that available drugs may potentially be repositioned as novel therapeutics for the treatment of CAD. Drug repositioning can save valuable time and money spent on preclinical and phase I clinical studies.
authors.forename: Mani P
authors.initials: MP
authors.lastname: Grover
authors.forename: Sara
authors.initials: S
authors.lastname: Ballouz
authors.forename: Kaavya A
authors.initials: KA
authors.lastname: Mohanasundaram
authors.forename: Richard A
authors.initials: RA
authors.lastname: George
authors.forename: Andrzej
authors.initials: A
authors.lastname: Goscinski
authors.forename: Tamsyn M
authors.initials: TM
authors.lastname: Crowley
authors.forename: Craig D H
authors.initials: CD
authors.lastname: Sherman
authors.forename: Merridee A
authors.initials: MA
authors.lastname: Wouters
mesh_terms: D016022:Case-Control Studies; D002986:Clinical Trials as Topic; D003324:Coronary Artery Disease / Q000235:genetics* / Q000628:therapy*; D019992:Databases as Topic; D055106:Genome-Wide Association Study; D006801:Humans; D058990:Molecular Targeted Therapy; D015203:Reproducibility of Results; D012984:Software